Should I Buy TAK Stock in 2026?

Data-driven analysis and honest assessment for Takeda Pharmaceutical Co Ltd

Analysis Updated:
CAUTIONSeveral concerns warrant careful consideration

Current Price: $17.78P/E: 81.1

Decision Score

5.0/10

Hold

Based on 6 fundamental factors

Score Breakdown:

Valuation (20%)2/10

Very high P/E of 81.1 suggests overvaluation

Growth (20%)5/10

Slow growth of 2%

Profitability (20%)4/10

Thin margins (0% net)

Financial Health (15%)5/10

Financial health data limited

Cash Flow (15%)10/10

Excellent FCF yield of 1581.4%

Insider Activity (10%)5/10

No recent insider activity

Key Investment Metrics

Current Price

$17.78

P/E Ratio

81.14

Revenue Growth

0.0%

Profit Margin

0.0%

Market Cap

$56.4B

Dividend Yield

0.04%

How TAK Compares to Competitors

Understanding how TAK stacks up against peers helps inform your investment decision.

How TAK Compares to Peers

Upcoming Events for TAK

+5 Reasons TO Buy TAK

1. High free cash flow yield of 1581.4%

strong

FCF yield above 5% means substantial cash generation for dividends, buybacks, or reinvestment.

2. High gross margins of 66%

moderate

Gross margins above 50% typically indicate strong brand value or intellectual property moats.

-5 Reasons NOT to Buy TAK

1. Expensive valuation at 81x earnings

high risk

P/E of 81 is significantly above averages. High expectations leave little room for disappointment.

2. Thin profit margins of 0.0%

high risk

Low margins provide little cushion against cost increases or pricing pressure.

3. Minimal revenue growth

low risk

Growth of 0.0% barely keeps pace with inflation.

Who Should Buy TAK?

Investment Profile

Risk Level

High

Recommended Holding Period

3-5 years

Best For:

  • Momentum Traders

    High-growth profile attracts momentum

Not Suitable For:

  • Growth Investors

    Limited 0% growth may disappoint

  • Value Investors

    Premium P/E of 81 doesn't fit value criteria

  • Income-Focused Retirees

    Low 0.0% yield

  • Risk-Averse Investors

    High risk may cause uncomfortable volatility

Consider These Alternatives

If you're interested in TAK, compare these Health Care peers:

Pro tip: Compare TAK directly with competitors using our comparison tool to see which stock better fits your criteria.

Get the Full Picture

Access AI-powered insights, DCF valuations, insider trading data, and real-time analysis for TAK

Frequently Asked Questions

What is TAK stock price today?

TAK (Takeda Pharmaceutical Co Ltd) stock is trading at $17.78 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is TAK stock going up or down today?

TAK stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy TAK stock now?

The decision to buy TAK depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is TAK a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for TAK based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is TAK stock overvalued or undervalued?

TAK currently trades at a P/E ratio of 81.14, which may indicate premium valuation. Our DCF calculator provides intrinsic value estimates to help determine if TAK is fairly priced.

What is TAK's P/E ratio?

TAK has a price-to-earnings (P/E) ratio of 81.14, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is TAK's market cap?

TAK (Takeda Pharmaceutical Co Ltd) has a market capitalization of $56.39 billion, making it a mid-cap stock.

What is TAK's price to book ratio?

TAK trades at a price-to-book (P/B) ratio of 1.17, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Similar Investment Decisions

Explore investment analyses for stocks similar to Takeda Pharmaceutical Co Ltd

Explore Categories

Disclaimer

This analysis is for informational purposes only and should not be considered financial advice. The decision score and recommendations are based on quantitative factors and do not account for all risks, your personal financial situation, or qualitative factors. Always do your own research and consider consulting with a financial advisor before making investment decisions.